MLYS logo

MLYS Mineralys Therapeutics, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$14.53
-0.80 (-5.22%)

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by…

Market Cap: $1.29Bmineralystx.com

Price

No data yet.

Social Signal Score

45
5d
—
30d
43
6 mentions
—
60d
45
11 mentions
—
90d
47
14 mentions
—
news: 14

Analyst Ratings

8 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 1Sell 0Strong Sell 0
Avg price target$29+99.6%
Low $29Median $29High $29
Current Consensus

Revenue

$0.00
$0.00
Dec 2021Sep 2026

Analyst Estimates

FY2025
$-2.39
$-2.51–$-2.15
6 analysts
FY2026
$-4.65
$-4.81–$-4.56
6 analysts
FY2027
$-2.47
$-3.33–$-1.72
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jon Congleton
Sector
Healthcare
Industry
Biotechnology
Employees
76
Beta
0.69
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
3.81
mineralystx.com